Interleukin 1 receptor antagonist and neurodegenerative diseases: the future treatment strategy

Neurodegenerative disorders encompass a range of conditions affecting the central nervous system (CNS) in which alterations neuronal structure and cellular dysfunction lead to progressive deterioration. Activation microglia expression inflammatory cytokine interleukin-1 (IL-1) CNS have become almost synonymous with neuroinflammation. Additionally, relentless activation IL-1 signalling pathway has been linked pathogenesis various disease states, ranging from Alzheimer (AD), Parkinson (PD) amyotrophic lateral sclerosis (ALS) multiple (MS). Moreover, growing body evidence inferred that impeding either pharmacologically or genetically models could reduce neuroinflammation delay progression. This review will therefore aim study role neurodegenerative diseases highlight key aspects warrant IL-1Ra as promising target for developing novel treatment conditions.